Irritable Bowel Syndrome Pipeline, Clinical Trials Analysis and NDA Approvals | 24+ Companies and 24+ Drugs

DelveInsight's, "Irritable Bowel Syndrome Pipeline Insight, 2023," report provides comprehensive insights about 24+ companies and 24+ pipeline drugs in Irritable Bowel Syndrome pipeline landscape. It covers the Irritable Bowel Syndrome pipeline drug profiles, including Irritable Bowel Syndrome clinical trial and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the Irritable Bowel Syndrome pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Irritable Bowel Syndrome NDA approvals (if any), and product development activities comprising the technology, Irritable bowel syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Key Takeaways from the Irritable Bowel Syndrome Pipeline Report
• DelveInsight's irritable bowel syndrome pipeline report depicts a robust space with 24+ companies and 24+ pipeline drugs for irritable bowel syndrome treatment.
• Key irritable bowel syndrome companies include Arena Pharmaceuticals, 4D Pharma, OrphoMed, Boston Pharmaceuticals, RedHill Biopharma Limited, Takeda, Cosmo Technologies, CinRx Pharma, Rottapharm, Synthetic Biologics, Biomica, Metacrine, MGC Pharma, Napo Pharmaceuticals, Novome Biotechnologies, Renexxion, Sentia Medical Sciences, Serentrix LLC, Vitality Biopharma, and others.
• Promising irritable bowel syndrome pipeline therapies in various stages of development include Olorinab, Blautix, ORP-101, BOS-589, BEKINDA, Rifamycin controlled-release, CIN 103, Crofelemer, RQ-00310941, AAT 730, and several others.
• The irritable bowel syndrome companies and academics are working to assess challenges and seek opportunities that could influence Irritable bowel syndrome R&D. The irritable bowel syndrome pipeline therapies under development are focused on novel approaches to treat/improve Irritable bowel syndrome.

Explore more information on the latest breakthroughs in the irritable bowel syndrome treatment landscape of the report and irritable bowel syndrome Pipeline Outlook @ https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Recent Developmental Activities of Irritable Bowel Syndrome Treatment Landscape
• In October 2022, Intrinsic Medicine and Phoenix Biotech Acquisition Corp. announced they have entered into a definitive business combination agreement.
• In September 2022, Novome Biotechnologies, Inc., a biotechnology company engineering first-in-class, living medicines for chronic diseases, announced the closing of a $43.5 million Series B financing.

Irritable Bowel Syndrome Overview
Irritable bowel syndrome (IBS) is a group of symptoms that occur together, including repeated pain in your abdomen and changes in your bowel movements, which may be diarrhea, constipation, or both. With IBS, you have these symptoms without any visible signs of damage or disease in your digestive tract. The most common symptoms of irritable bowel syndrome (IBS) are pain in your abdomen, often related to your bowel movements, and changes in your bowel movements. These changes may be diarrhea, constipation, or both, depending on what type of IBS you have. To diagnose irritable bowel syndrome (IBS), doctors review the symptoms and the medical and family history and perform a physical exam. The doctor will look for a certain pattern in the symptoms. In some cases, doctors may order tests to rule out other health problems.

Request a sample and discover the recent advances in Irritable bowel syndrome Pipeline Therapies, visit Irritable bowel syndrome Treatment Landscape @ https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Irritable Bowel Syndrome Emerging Drugs Profile

ORP-101: OrphoMed
ORP-101 is a new chemical entity designed to confer peripheral partial μ agonist and full κ receptor antagonist activity, enabling treatment of both IBS-D symptoms of dysmotility and pain without the risk of sphincter of Oddi spasm or pancreatitis. ORP-101 has been shown in preclinical studies to not cross the blood-brain barrier. ORP-101 successfully completed Phase 1 clinical trials and was granted FDA Fast Track designation in 2018. Regulatory path to NDA has been agreed with the FDA. Currently, it is in Phase II stage of clinical trial evaluation to treat Irritable bowel syndrome.

Blautix: 4D Pharma
Blautix® is a single strain Live Biotherapeutic product (LBP), being developed as a treatment for both IBS-C and IBS-D. Pre-clinical studies demonstrated its ability to address visceral hypersensitivity and other symptoms of IBS and increase microbiome diversity. A Phase I study in healthy volunteers and IBS patients showed that Blautix® was well tolerated and an improvement in symptoms was also reported relative to placebo. The Phase II BHT-II-002 trial demonstrated an impact on overall response with regards to bowel habit and abdominal pain in IBS-C and IBS-D. Blautix® was well tolerated, with a safety profile comparable to placebo.

Irritable Bowel Syndrome Therapeutic Assessment
There are approx. 24+ key companies which are developing the therapies for Irritable bowel syndrome. The companies which have their Irritable bowel syndrome drug candidates in the most advanced stage, i.e. phase II include OrphoMed.

Get to know more information about the Irritable bowel syndrome Emerging Drugs and Companies of the report @ https://www.delveinsight.com/report-store/irritable-bowel-syndrome-ibs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Irritable Bowel Syndrome Pipeline Report
• Coverage- Global
• Irritable bowel syndrome Companies- Arena Pharmaceuticals, 4D Pharma, OrphoMed, Boston Pharmaceuticals, RedHill Biopharma Limited, Takeda, Cosmo Technologies, CinRx Pharma, Rottapharm, Synthetic Biologics, Biomica, Metacrine, MGC Pharma, Napo Pharmaceuticals, Novome Biotechnologies, Renexxion, Sentia Medical Sciences, Serentrix LLC, Vitality Biopharma, and others.
• Irritable bowel syndrome Pipeline Therapies- Olorinab, Blautix, ORP-101, BOS-589, BEKINDA, Rifamycin controlled-release, CIN 103, Crofelemer, RQ-00310941, AAT 730, and several others.
• Irritable bowel syndrome Pipeline Segmentation: Phases, Product Type, Molecule Type, Mechanism of action, Route of administration

Table of Content
1. Introduction
2. Executive Summary
3. Irritable bowel syndrome: Overview
4. Irritable bowel syndrome Pipeline Therapeutics
5. Irritable bowel syndrome Therapeutic Assessment
6. Irritable bowel syndrome - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. ORP-101: OrphoMed
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Irritable bowel syndrome Key Companies
21. Irritable bowel syndrome Key Products
22. Irritable bowel syndrome- Unmet Needs
23. Irritable bowel syndrome- Market Drivers and Barriers
24. Irritable bowel syndrome- Future Perspectives and Conclusion
25. Irritable bowel syndrome Analyst Views
26. Irritable bowel syndrome Key Companies
27. Appendix

For further information, refer to the detailed Irritable bowel syndrome pipeline report, visit Irritable bowel syndrome Emerging Drugs & Companies @ https://www.delveinsight.com/report-store/irritable-bowel-syndrome-ibs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Trending Market Research Reports

CAR-T Pipeline @ https://www.delveinsight.com/report-store/car-t-pipeline-insight

Stem Cell Market @ https://www.delveinsight.com/report-store/stem-cell-market

Anastomosis Device Market @ https://www.delveinsight.com/report-store/anastomotic-leak-devices-market

Blastomycosis market @ https://www.delveinsight.com/report-store/blastomycosis-market

Oncolytic virus cancer therapy pipeline @ https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-pipeline-insight-2021

Superficial punctate keratitis @ https://www.delveinsight.com/report-store/superficial-punctate-keratitis-market

Persistent corneal epithelial defects market @ https://www.delveinsight.com/report-store/persistent-epithelial-defect-market

Ranibizumab biosimilar insights @ https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
Brucellosis market @ https://www.delveinsight.com/report-store/brucellosis-market

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.